Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Guignabert

Showing results (31-40 of 152) with videos related to

Pageof 16
Sort By:
Development (Cambridge, England)|August 1, 2008
SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesisNesrine El-Bizri, Christophe Guignabert, Lingli Wang, et al.
American Journal of Respiratory Cell and Molecular Biology|November 2, 2010
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertensionLy Tu, Laurence Dewachter, Benoit Gore, et al.
British Journal of Clinical Pharmacology|June 9, 2022
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysisAlex Hlavaty, Matthieu Roustit, David Montani, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 3, 2013
Pathogenesis of pulmonary arterial hypertension: lessons from cancerChristophe Guignabert, Ly Tu, Morane Le Hiress, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 26, 2014
Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertensionMarie-Camille Chaumais, Christophe Guignabert, Laurent Savale, et al.
International Journal of Clinical Pharmacy|August 14, 2018
Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertensionMarie-Camille Chaumais, Caroline O'Connell, Laurent Savale, et al.
Hypertension (Dallas, Tex. : 1979)|August 18, 2022
Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in RatsLy Tu, Raphaël Thuillet, Julie Perrot, et al.
Pulmonary Circulation|July 21, 2021
Pulmonary hypertension associated with neurofibromatosis type 2Hirohisa Taniguchi, Tomoya Takashima, Ly Tu, et al.
The Lancet. Respiratory Medicine|August 17, 2023
Treatment of pulmonary arterial hypertension: recent progress and a look to the futureMarc Humbert, Olivier Sitbon, Christophe Guignabert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 13, 2023
Central role of ubiquitin-specific protease 8 in leptin signaling pathway in pulmonary arterial hypertensionEtienne-Marie Jutant, Mustapha K Chelgham, Mina Ottaviani, et al.
Pageof 16

Showing results (31-40 of 152) with videos related to

Sort By:
Pageof 16
Development (Cambridge, England)|August 1, 2008
SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesisNesrine El-Bizri, Christophe Guignabert, Lingli Wang, et al.
American Journal of Respiratory Cell and Molecular Biology|November 2, 2010
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertensionLy Tu, Laurence Dewachter, Benoit Gore, et al.
British Journal of Clinical Pharmacology|June 9, 2022
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysisAlex Hlavaty, Matthieu Roustit, David Montani, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 3, 2013
Pathogenesis of pulmonary arterial hypertension: lessons from cancerChristophe Guignabert, Ly Tu, Morane Le Hiress, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 26, 2014
Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertensionMarie-Camille Chaumais, Christophe Guignabert, Laurent Savale, et al.
International Journal of Clinical Pharmacy|August 14, 2018
Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertensionMarie-Camille Chaumais, Caroline O'Connell, Laurent Savale, et al.
Hypertension (Dallas, Tex. : 1979)|August 18, 2022
Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in RatsLy Tu, Raphaël Thuillet, Julie Perrot, et al.
Pulmonary Circulation|July 21, 2021
Pulmonary hypertension associated with neurofibromatosis type 2Hirohisa Taniguchi, Tomoya Takashima, Ly Tu, et al.
The Lancet. Respiratory Medicine|August 17, 2023
Treatment of pulmonary arterial hypertension: recent progress and a look to the futureMarc Humbert, Olivier Sitbon, Christophe Guignabert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 13, 2023
Central role of ubiquitin-specific protease 8 in leptin signaling pathway in pulmonary arterial hypertensionEtienne-Marie Jutant, Mustapha K Chelgham, Mina Ottaviani, et al.
Pageof 16